GLP-1 medications, including Wegovy and Zepbound, have seen a surge in sales as scientists continue to uncover their broader effects on the body, extending beyond mere weight reduction.
However, Novo Nordisk announced on November 24 that a highly anticipated study investigating these drugs’ influence on Alzheimer’s disease revealed no significant benefit.
Novo Nordisk, the manufacturer of semaglutide (marketed as Wegovy for weight management and Ozempic for diabetes), stated that its medication offered no superior benefit compared to a placebo in two trials involving individuals with early-stage Alzheimer’s. Further data from these studies is slated for release at the Clinical Trials on Alzheimer’s Disease conference in early December, followed by presentations at the Alzheimer’s and Parkinson’s Diseases conferences in March 2026.
This two-year investigation enrolled over 3,800 participants diagnosed with mild cognitive impairment or mild dementia stemming from Alzheimer’s, with half randomly administered a daily semaglutide pill and the other half a placebo. Novo Nordisk reported that while those on the drug showed enhancements in specific biological indicators of Alzheimer’s, these improvements did not correspond to a deceleration in disease progression, as assessed by a standard cognitive evaluation encompassing memory, problem-solving, social interaction, and self-care. Researchers are awaiting more comprehensive data to determine if the observed biomarker improvements might represent initial indicators of potential efficacy, particularly when used in conjunction with other interventions such as lifestyle modifications and existing treatments.
Scientists had anticipated that these weight-loss medications could influence Alzheimer’s, given that inflammation plays a role in the neurodegenerative condition and these drugs appear to possess anti-inflammatory properties. Both animal studies and observational research involving individuals using the drug for diabetes or weight management had suggested a potential to impede Alzheimer’s progression.
There is a significant demand for novel Alzheimer’s therapies, as only two current treatments—lecanemab (from Eisai) and donanemab (from Lilly)—directly target the underlying causes of the disease. Both function by reducing amyloid plaque accumulation in the brain and can reduce disease progression by up to 30% in patients with mild-to-moderate forms. Maria Carrillo, chief science officer and medical affairs lead for the Alzheimer’s Association, commented, “These findings will aid in enhancing our comprehension of this drug class. Although this semaglutide tablet proved ineffective against Alzheimer’s, research into this category of medications will persist, as they might exert diverse effects.”
Eli Lilly, the producer of tirzepatide, another medication in this class, has not yet indicated whether it intends to research its product’s potential impact on Alzheimer’s disease.
Novo Nordisk announced its decision to cancel the scheduled one-year follow-up for trial participants.
